2012-09-11 23:28:34 - Search for a salivary biomarker candidate for chronic fatigue syndrome abstract earns Blue Ribbon Award
San Antonio, TX – Hyperion Biotechnology’s Vice President and Chief Scientific Officer, Dr. John Kalns, presented the abstract “Search for a novel salivary biomarker candidate for chronic fatigue syndrome” at the 2012 American Association for Clinical Chemistry (AACC) annual meeting and won the Blue Ribbon Award. Winners of the Blue Ribbon Award for Distinguished Abstracts are selected by the AACC’s National Academy of Clinical Biochemistry in recognition of their scientific excellence. Hyperion’s abstract was one of 32 winners selected from a pool of 888 accepted abstracts.
According to the abstract, Chronic Fatigue Syndrome (CFS) is a serious condition afflicting approximately one million people in the United States. There is no known cause for CFS and diagnosis is made by ruling out
all other possible causes of fatigue. Hyperion’s team members, Dr. Kalns, Darren Michael, Bianca Valle and Toni Whistler, set an objective to identify a salivary biomarker candidate that could be explored further for its ability to diagnose CFS. Dr. Kalns stated, “Our research in salivary biomarkers inspired us to focus on discovering a method to rapidly diagnosis CFS so patients can overcome this sometimes debilitating condition.”
In their abstract, the Hyperion team works through the rationale that “Salivary markers of fatigue associated with physical exertion have been reported, suggesting that saliva may provide a method for diagnosis of CFS.” Their methodology included clinical assessments where study participants produced saliva samples for biochemical assessment. In receiving the Blue Ribbon Award, Dr. Kaln’s said, “We are honored to receive recognition for our abstract. With continued research, we hope a rapid diagnostic tool for CFS will become available to help those afflicted.”
Hyperion Biotechnology received support for this research through a collaborative agreement with the Centers for Disease Control, Atlanta, GA.
ABOUT HYPERION BIOTECHNOLOGY
Hyperion Biotechnology, founded in 1998, is an 8(a), 8(m) EDWO, SDVO small business offering expertise with salivary biomarkers that can provide valuable insight into many problems. Hyperion also delivers high-quality research and staffing to government customers. Our upper-level management team members have doctoral degrees in scientific and clinical disciplines, giving Hyperion a unique grasp on the technical requirements of customers engaged in biomedical research. We understand the work because we’ve done it. www.hyperionbiotechnology.com Source: Hyperion Biotechnology, Inc.